Olive Diagnostics, an eHealth Ventures portfolio company, is on the cusp of receiving regulatory approval and beginning product launch for their game-changing technology, the world’s first optical sensor for passive urinalysis in real-time.
The scientific innovation combined with the ease of at-home monitoring empowers patients to better understand and manage their health and wellbeing. They are currently in a financing round and have recently secured additional investment funds to support their post-Seed stage R&D.
Urinalysis is one of the most frequently employed tools for the diagnosis and monitoring of a wide range of medical conditions. Unfortunately, the accessibility of urinalysis is limited to either lab testing or a variety of inaccurate, unsanitary, and inconvenient home methods.
Increasing the accessibility and affordability of home-based urinalysis diagnostics is essential to healthcare digitization. When people can self-monitor for disease prevention and early detection with comfort and accuracy from their own home, healthcare and outcomes improve, leading to healthier populations.
Olive Diagnostics has developed the world’s first passive and non-invasive urinalysis sensor that is able to provide real-time health alerts, early detection, and progression of diseases in a convenient home setting.
The Olive KG, Olive Diagnostics’ primary device, can easily attach to any toilet and analyze the urine stream through a combination of advanced spectroscopy sensors and AI capabilities to detect a number of markers present in the urine that can indicate a patient’s health status. The device enables continuous monitoring and easy detection of biomarkers from the body, and can be used for both self and remote monitoring. The scientific innovation combined with the ease of at-home monitoring empowers patients to better understand and manage their health and wellbeing.
Olive Diagnostics expects the first market introduction of the Olive KG in Q1 of 2022, to European elder care facilities and women’s health clinics.
Olive Diagnostics has gained backing from several high-profile investors such as e-Health Ventures and Maccabi Foundation (the private investment arm of Israel’s premiere healthcare giant Maccabi Healthcare Services).
About eHealth Ventures
The eHealth Ventures partnership is a leading investor in early-stage digital health companies.
It includes 2 VC funds and a technological incubator with an exclusive focus on digital health and significant government non-dilutive funding. Partners include Maccabi (a leading Israeli HMO), Amgen (global biotech giant), the Mayo Clinic, Medison Ventures, Arad Investments, and the Hadar Group. The team has reviewed over 1,650 companies to date and invested in a portfolio of 24 highly innovative companies (digital diagnostics, therapeutics, home care and Bioconvergence).